development agreement with Adalvo for semaglutide injection -statement
06/05/2025 07:07
May 6 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says: IT ENTERS A GLOBAL CO-DEVELOPMENT AGREEMENT WITH ADALVO FOR SEMAGLUTIDE INJECTION -STATEMENT AGREEMENT IS FOR PROPOSED BIOEQUIVALENT TO SEMAGLUTIDE INJECTION, A GLP-1 RECEPTOR AGONIST INDICATED FOR CHRONIC WEIGHT MANAGEMENT THE AGREEMENT COVERS GLOBAL RIGHTS, WITH BOTH COMPANIES SHARING DEVELOPMENT COSTS AND NET PROFITS ACROSS EACH OTHER'S MARKETS Source text: [https://bet.hu/newkibdata/129251875/Semaglutide_6May2025_ENG.pdf] Further company coverage: GDRB.BU (Reporting by Anita Komuves) ((KOMUVES.Anita@thomsonreuters.com;))
Recent news on Richter Gedeon Vegyeszeti Gyar Nyrt
See all newsAI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection
Brief: Hungary's Richter and Acrux agree to license transdermal Estradiol spray for Australia
Brief: Hungary's Richter Says 2026 Guidance Fully Reiterated High-Single-Digit Growth In Revenues And Clean EBIT (At Constant Exchange Rates)
Brief: Hungary's Richter says European Commission granted approval for Tuyory, its biosimilar to Tocilizumab